Palantir’s Rally Relies on US Momentum as a $440 Million UK Contract Hangs in the Balance
Published on 07/08/2026 at 11:02 | Redaktion boerse-global.de
Palantir’s stock has been a study in contradiction this year. The company’s government business is so deeply embedded in US national security infrastructure that rival software faces an almost insurmountable switching cost. Yet the same shares that benefit from that structural moat have been whipsawed by the rotating appetite for AI plays — and by a single contract decision in London that could redefine the international narrative.
The rotation out of AI software into semiconductor stocks punished Palantir hard in June. The S&P 500 fell 1.1% that month, the Nasdaq Composite dropped 2.8%, and Palantir was caught in the downdraft. But the tide began to turn in July, spurred by news that the data-analytics firm had deepened its partnership with chip giant Nvidia. Palantir is now integrating Nvidia’s Nemotron AI models directly into its own platform, strengthening the offerings it provides to the US government and allied nations. The alliance directly counters the criticism that Palantir’s software could be bypassed in a world focused on raw silicon power.
The stock closed at €117.62 on Tuesday, up more than 6% over the prior week, though it remains down roughly 18% year to date. On a technical level, the recent bounce off the annual low of €93.30 has produced a clear signal: a sustained move above the short-term trendline at €115.13 would mark a confirmed chart reversal.
A Fresh Vote of Confidence from the Street
DA Davidson has added its own catalyst. The firm upgraded Palantir from Neutral to Buy and lifted its price target from $165 to $175. Analysts there argue that Palantir functions as an indispensable AI orchestration layer — not a direct competitor to large language models — and view the recent earnings-estimate correction as an entry point for investors.
Should investors sell immediately? Or is it worth buying Palantir?
The bull case rests on the domestic numbers. In the most recent quarter, Palantir’s US commercial revenue hit $595 million, up 133% year over year and 18% sequentially. The US government segment contributed $687 million, growing 84% annually and 21% quarter on quarter. Adjusted free cash flow reached $925 million, and the operating margin stood at an eye-popping 57%. For optimists, this momentum makes any valuation concern a secondary issue.
The ÂŁ330 Million Cloud Over London
But across the Atlantic, a flagship project is wobbling. Palantir holds a contract to manage data infrastructure for the UK’s National Health Service, valued at £330 million (roughly $440 million). The UK Parliament’s Science and Technology Committee has recommended against renewing the agreement, which expires early next year. A final government decision has not been made, but the risk is material: if the NHS contract falls through, Palantir’s international government growth story takes a direct hit.
The bear case is built on the thin margin for error that the stock’s valuation allows. Even after sliding 31% to 37% from its late-2025 peak, the shares still trade at 135 to 146 times expected earnings, with a revenue multiple between 59 and 62. A reverse discounted cash-flow model suggests Palantir would need to generate more than $100 billion in annual revenue —17 to 25 times its current growth rate — to justify the price. US agencies tend to spread IT spending across multiple vendors, structurally capping how dominant any single supplier can become in the federal market.
Palantir at a turning point? This analysis reveals what investors need to know now.
Insider selling has added to the overhang, and the combination of rich multiples, a dependent international pipeline, and the impending NHS verdict keeps the stock tethered to either a definitive export of the US model or a sobering revaluation.
Waiting for the Next Data Points
The average analyst price target for Palantir stands at €160.08, implying roughly 36% upside from current levels. That gap has remained stubbornly wide for months, suggesting the market is demanding proof rather than promises. Two events could close that gap — or widen it further. The British government’s formal decision on the NHS contract is expected in the coming months, and the next quarterly earnings report will show whether the blistering US growth rate from the first half of the year is sustainable. Should the domestic figures falter, the premium baked into the stock will evaporate quickly.
Ad
Palantir Stock: New Analysis - 8 July
Fresh Palantir information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
